7799 Herong Tech: IND Application for B10 L-BPA Injection

Herong Tech announced that it has filed an Investigational New Drug (IND) application with the Taiwan Food and Drug Administration (TFDA) for its B10 L-BPA injection. The study aims to evaluate the efficacy and safety of Boron Neutron Capture Therapy (BNCT) for recurrent locally advanced or metastatic triple-negative breast cancer. This is a Phase II clinical trial. Triple-negative breast cancer remains one of the most challenging areas in oncology with high unmet medical needs. If successful, this could expand the application of BNCT in solid tumors and create new growth opportunities. The trial is primarily for academic and medical research purposes, with the company acting as the sponsor.